Table 3.
Univariable and multivariable Cox regression analyses for progression-free survival
| Factor |
Univariate analysis |
Multivariate analysis |
||
| HR (95%CI) | P value | HR (95%CI) | P value | |
| Age in yr | 0.99 (0.97-1.01) | 0.215 | - | - |
| Sex as female/male | 0.73 (0.42-1.29) | 0.283 | - | - |
| Tumor size in cm | 1.04 (1.00-1.09) | 0.0401 | 1.04 (0.99-1.08) | 0.098 |
| Number of tumors | ||||
| 1 | - | 0.0041 | - | 0.0281 |
| ≥ 2 | 0.28 (0.12-0.62) | 0.0021 | 0.36 (0.15-0.85) | 0.0191 |
| Infiltrative | 0.48 (0.23-1.01) | 0.052 | 0.60 (0.28-1.30) | 0.193 |
| Portal vein invasion | ||||
| No invasion | - | 0.566 | - | - |
| Stage I-II | 0.75 (0.43-1.30) | 0.303 | - | - |
| Stage III-IV | 0.89 (0.54-1.47) | 0.645 | - | - |
| Extrahepatic metastasis | 1.25 (0.83-1.89) | 0.285 | - | - |
| Child-Pugh stage, A/B | 1.13 (0.62-2.06) | 0.702 | - | - |
| Performance status, 0/1 | 1.10 (0.73-1.66) | 0.651 | - | - |
| AFP in ng/mL | 1.00 (1.00-1.00) | 0.050 | 1.00 (1.00-1.00) | 0.212 |
| Albumin in g/L | 0.97 (0.93-1.02) | 0.246 | - | - |
| Total bilirubin in mg/mL | 1.02 (1.00-1.04) | 0.088 | 1.00 (1.00-1.02) | 0.960 |
| GGT | 1.00 (1.00-1.00) | 0.0031 | 1.00 (1.00-1.00) | 0.0321 |
| ALT | 1.00 (1.00-1.01) | 0.114 | - | - |
| AST | 1.00 (1.00-1.01) | 0.0081 | 1.00 (1.00-1.01) | 0.149 |
| Targeted treatment, yes/no | 0.86 (0.50-1.49) | 0.589 | - | - |
| S-1 treatment, yes/no | 0.90 (0.61-1.32) | 0.585 | - | - |
1
The P value is < 0.05. CI: Confidence interval; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; HR: Hazard ratio.